HuMax-CD4

Phase 3Small molecule

Genmab

HuMax-CD4 is one of 138 small molecule programs targeting Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

137

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Cutaneous T-Cell LymphomaActive, not recruiting

Mycosis FungoidesActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

LymphomaPhase 2

Active, not recruiting

Cutaneous T-Cell LymphomaPhase 2/Phase 3

Active, not recruiting

Mycosis FungoidesPhase 3

Active, not recruiting

Rheumatoid ArthritisPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

HuMax-CD4

Genmab

Phase 3

2 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Zofran

Novartis

Preclinical

2 4

Norvir

AbbVie

Preclinical

1 5

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

PEG-Intron

1 7

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

3 8

CAR-T

HHebei Senlang Biotechnology Inc., Ltd.

Preclinical

3 9

Stem Cells

KKang Stem Biotech Co., Ltd.

Preclinical

2 10

JY231

SShenzhen Genocury Biotech Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lymphoma2 trials

Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.

Completed· Genmab logo

Genmab·Phase 2·NCT00071071·25 enrolled

Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.

Completed· Genmab logo

Genmab·Phase 2·NCT00071084·22 enrolled

Mycosis Fungoides1 trial

Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome

Terminated·EEmergent Product Development Seattle LLC·Phase 3·NCT00127881·76 enrolled

Rheumatoid Arthritis1 trial

Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker

Terminated· Genmab logo

Genmab·Phase 2/3·NCT00042406·83 enrolled

Cutaneous T-cell lymphoma1 trial

HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma

Completed· Emergent BioSolutions logo

Emergent BioSolutions·Phase 2/3·NCT00877656·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for HuMax-CD4. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HuMax-CD4 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HuMax-CD4. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Genmab company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Genmab

HuMax-CD4

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lymphoma2 trials

Mycosis Fungoides1 trial

Rheumatoid Arthritis1 trial

Cutaneous T-cell lymphoma1 trial

References

Drug Info

Quick Facts

Related News